Health
Innovent Announces Phase 2 Clinical Study Of Picankibart (IBI112) In Chinese Patients With Ulcerative Colitis Met Primary Endpoint
(MENAFN - PR Newswire) SAN FRANCISCOand SUZHOU,China, Oct. 16, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, ...
By: menafn
- Oct 17 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS
Share this page
Guest Posts by Easy Branches In Chinese Patients With Ulcerative Colitis Met Primary Endpoint&url=https://easybranches.com/feed/kr/health/10581285&media=https://easybranches.com/feed/assets/images/default.png){kind=link}
